Odile R.
- Country
- France
- Department
- IUCT Oncopole Médecine Interne
Research Overview
- Phase II Study of Imetelstat Sodium in High‑Risk MDS and AML Patients Refractory to Hypomethylating Agent Therapy
- Randomized Study of Early Versus Delayed Epoetin Alfa Initiation in Lower-Risk Myelodysplastic Syndromes with Non-Transfusion-Dependent Anemia Without del(5q)
- Phase II Multicenter Study of Ivosidenib in IDH1-Mutated Myelodysplastic Syndrome Patients
Data & Insights
Has run more than one trial at 29 of 96 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with particular emphasis on cases involving specific genetic mutations.
- IDH1 and IDH2 mutated conditions
- Treatment-resistant hematologic disorders
- Advanced myeloid malignancies
The research focuses on innovative therapeutic approaches for patients with genetic mutations affecting blood cell development.
Targeted Therapies
Expertise in developing and implementing mutation-specific treatments for hematologic disorders, particularly focusing on targeted molecular therapies.
- Novel therapeutic agents
- Mutation-targeted approaches
- Personalized treatment strategies
The investigator works with advanced therapeutic compounds designed to address specific genetic alterations in blood disorders.
Treatment-Resistant Disease
Specialized focus on treating refractory hematologic conditions, particularly in patients who have failed standard therapeutic approaches.
- HMA-resistant disease
- Second-line treatments
- Alternative therapeutic strategies
Research interests include developing effective treatments for patients who have not responded to conventional therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.